8-K: Esperion Reports Strong Q2 2025 Growth, Eyes 2026 Profitability

Esperion Therapeutics reported robust second-quarter 2025 financial results, driven by significant U.S. net product revenue growth and achieving its first quarter of operating income from ongoing business.

Summary

• Total revenue for the second quarter of 2025 was $82.4 million, representing a 12% increase year-over-year.
• U.S. net product revenue for Q2 2025 grew 42% year-over-year to $40.3 million.
• Total retail prescription equivalents increased by approximately 10% from the first quarter of 2025.
• Reached settlement agreements with three ANDA filers, preventing them from marketing generic versions of NEXLETOL (bempedoic acid) prior to 2040.
• Achieved the first quarter of operating income from ongoing business in the company's history, approximately $15.0 million.
• Expects to achieve sustainable profitability beginning in the first quarter of 2026.
• Royalty revenue increased 30% sequentially to $13.6 million.
• Net loss for Q2 2025 was $4.8 million, a significant improvement compared to a net loss of $61.9 million in Q2 2024.
• Cash and cash equivalents totaled $86.1 million as of June 30, 2025.
• Full year 2025 operating expenses are reiterated to be in the range of $215 million to $235 million, including approximately $15 million in non-cash stock compensation.

Sentiment

Score: 8

Explanation: The filing demonstrates strong commercial execution, significant revenue growth in key segments, achievement of operating income, and extended patent protection, all contributing to a positive outlook for future profitability. While cash decreased, the operational improvements are substantial and strategic milestones are being met.

Positives

• Total revenue for Q2 2025 grew 12% year-over-year to $82.4 million.
• U.S. net product revenue for Q2 2025 increased 42% year-over-year to $40.3 million.
• Total retail prescription equivalents increased by approximately 10% from the first quarter.
• Successfully reached settlement agreements with three ANDA filers, protecting NEXLETOL's market exclusivity until 2040.
• Achieved the first quarter of operating income from ongoing business, approximately $15.0 million, marking a significant year-over-year improvement.
• Expects sustainable profitability to begin in the first quarter of 2026.
• Royalty revenue increased 30% sequentially to $13.6 million, indicating strong performance from European partnerships.
• Increased the number of healthcare practitioners writing prescriptions for NEXLETOL and NEXLIZET to more than 28,000 in Q2 2025.
• Improved access and reimbursement support, with all targeted business approval rates increasing to over 80%.
• Net loss significantly reduced to $4.8 million in Q2 2025 from $61.9 million in Q2 2024.
• Research and development expenses decreased by 37% year-over-year to $7.2 million due to decreased clinical study and compensation costs.
• Selling, general and administrative expenses decreased by 11% year-over-year to $39.5 million, primarily due to reduced media and marketing costs.
• Welcomed Robert Hoffman and Craig Thompson, seasoned executives with commercial and operational expertise, to the Board of Directors.

Negatives

• Total revenue for the six months ended June 30, 2025, decreased 30% year-over-year to $147.4 million, primarily due to the absence of one-time settlement agreement milestones received in the comparable 2024 period.
• Collaboration revenue decreased approximately 7% for the three months and 54% for the six months ended June 30, 2025, compared to comparable periods in 2024, also driven by the 2024 settlement milestone.
• Net loss for the six months ended June 30, 2025, was $45.2 million, compared to a net loss of $0.9 million for the comparable period in 2024, largely influenced by the 2024 one-time milestone.
• Cash and cash equivalents decreased to $86.1 million as of June 30, 2025, from $144.8 million as of December 31, 2024.
• Total stockholders' deficit increased to $(425.6) million as of June 30, 2025, from $(388.7) million as of December 31, 2024.

Risks

• Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels, potentially leading to gout.
• There is an increased risk of tendon rupture or injury associated with bempedoic acid, particularly in patients over 60, those taking corticosteroids or fluoroquinolones, patients with renal failure, and those with previous tendon disorders.
• NEXLIZET and NEXLETOL are contraindicated in patients with a prior hypersensitivity to bempedoic acid or ezetimibe or any excipients, with serious hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria reported.
• Common adverse reactions in primary hyperlipidemia trials include upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, arthralgia, sinusitis, fatigue, influenza, urinary tract infection, nasopharyngitis, and constipation.
• Common adverse reactions in the cardiovascular outcomes trial include hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.
• There is potential for serious adverse reactions in a breast-fed infant, and breastfeeding is not recommended during treatment.
• Actual results may differ significantly from forward-looking statements due to various risks and uncertainties, including those related to net sales, profitability, growth of commercial products, clinical activities, supply chain, commercial development, launch plans, and outcomes of legal proceedings and settlements.

Future Outlook

The company reiterates its expectation for full year 2025 operating expenses to be in the range of $215 million to $235 million. Based on strong performance, the company now expects to achieve sustainable profitability beginning in the first quarter of 2026. Plans include launching a consumer television ad on connected TV platforms and advancing its clinical pipeline and strategic portfolio expansion. Global expansion efforts are on track with expected market approvals in Japan (H2 2025), Canada (Q4 2025), Israel (H1 2026), and Australia (Q4 2026).

Management Comments

• "Our second quarter results reflect the strength of our commercial execution and the growing adoption of our bempedoic acid therapies in cardiovascular disease prevention."
• "With more than 15% sequential quarterly growth and 42% year-over-year quarterly growth in net U.S. product sales, we are delivering on our commitment to patients and shareholders alike."
• "The three recent ANDA settlements also demonstrate our commitment to protecting our intellectual property portfolio and reflect our belief in the strength of our patents."
• "As we continue to expand access to these life-saving therapies through improved payer dynamics and prepare to launch our consumer television ad on connected TV, such as Hulu and NBC Sports, we remain focused on driving sustained revenue growth."
• "In parallel, we are advancing our clinical pipeline and pursuing strategic portfolio expansion to shape the future of cardiovascular disease prevention worldwide."
• "Importantly, we delivered our first quarter of operating income from ongoing business and expect our continued growth and achievements to support sustainable profitability beginning in the first quarter of 2026."
• "With strong momentum, we are moving forward with confidence."
• "As we advance our growing leadership in cardiovascular diseases, we are proud to welcome Robert Hoffman and Craig Thompson, both seasoned executives with a wealth of commercial and operational expertise, to our Board of Directors."

Industry Context

The company operates in the highly competitive cardiovascular disease prevention market, focusing on oral, once-daily, non-statin medicines for patients with elevated LDL-C, particularly those unable to take statins or with established cardiovascular disease. The successful ANDA settlements highlight the critical importance of intellectual property protection in the pharmaceutical sector. The global expansion strategy, including partnerships in Europe, Japan, Canada, Israel, Australia, and New Zealand, indicates a broad effort to capture market share and diversify revenue streams beyond the U.S. The ongoing development of ATP citrate lyase inhibitors (ACLYi) positions the company for future innovation in lipid-lowering therapies, aligning with the industry's continuous pursuit of novel treatment modalities.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry comparison. The focus is on the company's internal growth metrics and strategic milestones.

Management Changes

Legal Proceedings

• Reached settlement agreements with three ANDA filers not to market generic versions of NEXLETOL (bempedoic acid) prior to 2040, resolving potential intellectual property disputes.

Stakeholder Impact

• Shareholders: Positive impact due to strong U.S. product revenue growth, achievement of operating income, extended patent protection until 2040, and a clear path to sustainable profitability from Q1 2026.
• Patients: Increased access to NEXLETOL and NEXLIZET through improved payer dynamics and an expanded prescriber base, along with continued development of therapies for cardiovascular disease prevention.
• Healthcare Providers (HCPs): Enhanced support and education regarding reimbursement, fostering greater confidence in prescribing the company's therapies.
• Employees: The company's strong growth and projected sustainable profitability suggest a stable and positive outlook for employees.
• Partners: Existing partnerships (e.g., Daiichi Sankyo Europe) show strong revenue growth, and new market approvals in various territories indicate successful collaboration and expansion opportunities.

Next Steps

• Launch a consumer television advertisement on connected TV platforms, including Hulu and NBC Sports.
• Advance the clinical pipeline and pursue strategic portfolio expansion to shape the future of cardiovascular disease prevention.
• Otsuka Pharmaceutical Co., Ltd. (Japan partner) is on track for expected approval and National Health Insurance pricing in the second half of 2025.
• Complete technology transfer for manufacturing of NILEMDO and NUSTENDI to Daiichi Sankyo Europe (DSE), with certain working capital benefits expected in 2025.
• Health Canada review for NEXLETOL and NEXLIZET is on track for expected market approval in the fourth quarter of 2025.
• Neopharm Israel (Israel partner) remains on track for market approval of NEXLETOL and NEXLIZET in the first half of 2026.
• CSL Seqirus (Australia and New Zealand partner) expects market approval in Australia for NEXLETOL and NEXLIZET in Q4 2026.
• Continue to build on its success with its next generation program focused on developing ATP citrate lyase inhibitors (ACLYi).

Key Dates

Recommendation

The company has demonstrated a significant operational turnaround, achieving its first quarter of operating income and projecting sustainable profitability starting Q1 2026. Strong U.S. product revenue growth (42% Y/Y) and successful patent settlements extending exclusivity until 2040 substantially de-risk future revenue streams. Global expansion efforts are progressing well, indicating future growth avenues. The substantial reduction in net loss and controlled operating expenses further support a positive financial trajectory, making it an attractive investment for long-term growth.

Keywords

Esperion, ESPR, biopharmaceutical, cardiovascular disease, LDL-C, cholesterol, NEXLETOL, NEXLIZET, bempedoic acid, statin intolerance, Q2 earnings, financial results, patent settlement, drug development, lipid-lowering